Skip to content
Screener

Boston Scientific BSX Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

TFX
TeleflexTFX
$1.41B-18.4%
Haemonetics logo
HaemoneticsHAE
$374.83M+13.4%
Globus Medical logo
Globus MedicalGMED
$429.85M+36.7%
CONMED logo
CONMEDCNMD
ClearPoint Neuro logo
ClearPoint NeuroCLPT
Stereotaxis logo
StereotaxisSTXS

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$71.46B-53.2%
P/E19.5×-41.7×
P/S3.4×-4.9×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 6:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885725-26-000033
(in millions)As of March 31, 2026 / Gross Carrying AmountAs of March 31, 2026 / Accumulated Amortization/ Write-offsAs of December 31, 2025 / Gross Carrying AmountAs of December 31, 2025 / Accumulated Amortization/ Write-offs
Technology-related$14,985$(9,549)$14,692$(9,346)
Patents497(387)493(382)
Other intangible assets2,511(1,766)2,482(1,732)
Amortizable intangible assets$17,992$(11,702)$17,667$(11,461)
Goodwill$28,436$(9,900)$28,182$(9,900)
IPR&D$770$813
Indefinite-lived intangible assets$770$813

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Boston Scientific's finite-lived intangible assets, accumulated amortization?
Boston Scientific (BSX) reported finite-lived intangible assets, accumulated amortization of $11.7B in Q1 2026.
How has Boston Scientific's finite-lived intangible assets, accumulated amortization changed year-over-year?
Boston Scientific's finite-lived intangible assets, accumulated amortization increased by 8.1% year-over-year, from $10.82B to $11.7B.
What is the long-term trend for Boston Scientific's finite-lived intangible assets, accumulated amortization?
Over 5 years (2020 to 2025), Boston Scientific's finite-lived intangible assets, accumulated amortization has grown at a 8.0% compound annual growth rate (CAGR), from $7.81B to $11.46B.

Ask your AI about Boston Scientific's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude